Nutex Health, Inc. (NUTX)

LOS ANGELES , Dec. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

HOUSTON , Dec. 4, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 25 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced that its Board of Directors has approved an extension of the previously authorized stock repurchase program. The program, originally announced on August 14, 2025, authorized the repurchase of up to $25.0 million of the Company's common stock over a six-month period, commencing upon the filing of the Company's Form 10-Q for the quarter ended June 30, 2025.

Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript

Nutex Health Inc. recently posted Q2 and Q3 results, showing strong revenue growth and operating cash flow. NUTX's accounts receivable balance continues to rise, raising questions about the collectability of revenue booked under the No Surprises Act. NUTX's valuation metrics compare very favorably to its peers across the board.

HOUSTON , Nov. 26, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), is aware of a short seller report issued on November 25, 2025 by Capybara Research. Based on publicly available information, Capybara Research as an entity seems not to exist.

HOUSTON , Nov. 24, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 25 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the reopening of Red River ER & Hospital in Sherman, Texas. The staff of medical experts at Red River ER & Hospital are bringing the community 24/7/365 days of concierge-level care.

Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5% Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 million Diluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024 EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4% Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for the first half nine months of 2024, an increase of 1408.6% Net cash from operating activities of $177.7 million for the first nine months of 2025 HOUSTON , Nov. 19, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced financial results for the three and nine months ended September 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Total revenue of $455.8 million for the first half of 2025   versus $143.5 million for the first half of 2024, an increase of 217.5% Net income attributable to Nutex Health Inc. of $3.5 million for the first half of 2025 versus net loss of $0.7 million for the first half of 2024, an increase of $4.2 million Diluted income per share of $0.55 for the first half of 2025 versus a loss per share of $0.15 for the first half of 2024 EBITDA of $51.1 million for the first half of 2025 versus $15.6 million for the first half of 2024, an increase of 227.4% Adjusted EBITDA of $144.4 million for the first half of 2025 versus $6.4 million for the first half of 2024, an increase  of 2144.2% Net cash from operating activities of $78.2 million for the first half of 2025 On August 14, 2025 ,   the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company's common stock HOUSTON , Nov. 18, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Total revenue of $211.8 million for Q1 2025 versus $67.5 million for Q1 2024, an increase of 214.0% Net income attributable to Nutex Health Inc. of $21.2 million for Q1 2025 versus net loss of $0.4 million for Q1 2024, an increase of $21.6 million. Diluted income per share of $3.33 for Q1 2025 versus a loss per share of $0.08 for Q1 2024 EBITDA of $51.5 million for Q1 2025 versus $7.1 million for Q1 2024, an increase of 624.7% Adjusted EBITDA of $72.8 million for Q1 2025 versus $(0.4) million for Q1 2024, an increase of $73.2 million Net cash from operating activities of $51.0 million for Q1 2025 The Company believes its arbitration efforts through the Independent Dispute Resolution (IDR) process have resulted in an increase in fair and reasonable payments from insurance companies HOUSTON , Nov. 18, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced restated first quarter financial results for the three months ended March 31, 2025.

FULL YEAR 2024 HIGHLIGHTS: Total revenue of $479.9 million for the year 2024 versus $247.6 million for the year 2023, an increase of 93.8% Net income attributable to Nutex Health Inc. of $52.1 million for 2024 versus net loss of $45.8 million for 2023 Diluted income per share of $9.69 for 2024 versus a loss per share of $10.39 for 2023 EBITDA of $98.8 million for 2024 versus $(22.5) million for 2023 Adjusted EBITDA of $124.1 million for 2024 versus $10.8 million for 2023, an increase of 1046.1% Net cash from operating activities of $23.2 million for the year 2024 HOUSTON , Nov. 18, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced restated fourth quarter 2024 and fiscal year 2024 financial results for the twelve months ended December 31, 2024. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of  Nutex securities between August 8, 2024 and August 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) securities between August 8, 2024 and August 14, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON NUTEX HEALTH INC. (NUTX), CLICK HERE TO PARTICIPATE IN THE SECURIT.

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”), of the important October 21, 2025 lead plaintiff deadline.

Nutex allegedly hid HaloMD's insurance fraud scheme, misstated internal controls and stock comp, and overstated its business and financial prospects.

NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025.

NUTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Oct. 21, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, misleading shareholders and triggering substantial losses.